Stock Taper
SCREENER COMPARE ANY 2 STOCKS
KARD
KARDIGAN, INC.
NASDAQ
$20.02
▼ DOWN 3.75% (-0.78)

KEY STATISTICS

Market Cap$1.79 B
52w High$27.00
52w Low$16.25
Dividend Yield—
Frequency—
P/E-9.14
Volume196.56K
Shares Out.89.34M

COMPANY

LEADERSHIP

Tassos Gianakakos
CHIEF EXECUTIVE
Tassos Gianakakos

ABOUT

SECTOR
Healthcare
WENT PUBLIC
June 18, 2026
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
241

PRICE TARGET

Target High$40.00
Target Low$37.00
Target Median$38.50
Target Consensus$38.50

UPCOMING EARNINGS

DateSep 2, 2026
DayWednesday
Rev. Est.—
SEP
2
WED

PRICE

$20.02 ▼ DOWN 3.75% (−$0.78)
$20.10$20.40$20.709:34 AM10:38 AM11:42 AM12:47 PM1:51 PM2:55 PM3:59 PM20.02

About Kardigan, Inc.

http://www.kardigan.bio ↗

Kardigan is a clinical-stage precision therapeutics company developing medicines like Danicamtiv, Ataciguat, and Tonlamarsen to target the root causes of unmet cardiovascular diseases.

INDUSTRY

Biotechnology

A SERVICE KARDIGAN, INC. IS KNOWN FOR

Development of Danicamtiv

Danicamtiv, Kardigan's lead drug candidate, is a clinical-stage cardiac myosin activator developing a potential first-in-class therapy for genetic dilated cardiomyopathy, a condition with no current targeted treatments.

COMPETITORS

COMPETITOR
BBIO COMPARE
CYTK COMPARE
RCKT COMPARE
TNYA COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
17
LISTED HERE
2
RANKED BY POSITION SIZE
VTS.AX
0.00% · 94.5K
GSC
0.26% · 35.3K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
55.02%
HOLDERS
55
TOP 12 OF 55 · RANKED BY POSITION SIZE
Schf (Gpe), LLC
16.9M sh · $403.47M
Fmr LLC
8.9M sh · $212.48M
Perceptive Advisors LLC
8.2M sh · $195.59M
T. Rowe Price Investment Management, Inc.
4.2M sh · $100.34M
Capital Research Global Investors
3.6M sh · $85.83M
Jpmorgan Chase & Co
1.8M sh · $46.38M
Alliancebernstein L.P.
1.5M sh · $36.61M
Liberty Mutual Group Asset Management Inc.
1.2M sh · $28.53M
Paradigm Biocapital Advisors LP
900.0K sh · $21.46M
Price T Rowe Associates Inc /Md/
658.8K sh · $15.71M
Goldman Sachs Group Inc
645.0K sh · $15.38M
Deep Track Capital, LP
600.0K sh · $14.31M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book2
Overall Score2

INSIDER TRADES

★
DIRECTOR
PERCEPTIVE ADVISORS LLC
Purchase · 20.7K shares
2026-06-17
★
10 PERCENT OWNER
HRTG GPE, LLC
— · 3.2M shares
2026-06-17
★
DIRECTOR, 10 PERCENT OWNER:
BERNS PAUL L
Purchase · 1.3M shares
2026-06-22
★
DIRECTOR, 10 PERCENT OWNER:
ARCH Venture Partners XIII, LLC
Purchase · 1.3M shares
2026-06-22

MOST RECENT ANALYST GRADES

GRADE SUMMARY
OVERWEIGHT 1
1 GRADES IN THE LAST 12 MONTHS
JP Morgan OVERWEIGHT